Diagnostic biomarkers for active tuberculosis: progress and challenges
Tuberculosis (TB) is a leading cause of morbidity and mortality from a single infectious agent, despite being preventable and curable. Early and accurate diagnosis of active TB is critical to both enhance patient care, improve patient outcomes, and break Mycobacterium tuberculosis ( Mtb ) transmissi...
Uloženo v:
| Vydáno v: | EMBO molecular medicine Ročník 14; číslo 12; s. e14088 - n/a |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
London
Nature Publishing Group UK
07.12.2022
EMBO Press John Wiley and Sons Inc Springer Nature |
| Témata: | |
| ISSN: | 1757-4676, 1757-4684, 1757-4684 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Tuberculosis (TB) is a leading cause of morbidity and mortality from a single infectious agent, despite being preventable and curable. Early and accurate diagnosis of active TB is critical to both enhance patient care, improve patient outcomes, and break
Mycobacterium tuberculosis
(
Mtb
) transmission cycles. In 2020 an estimated 9.9 million people fell ill from
Mtb
, but only a little over half (5.8 million) received an active TB diagnosis and treatment. The World Health Organization has proposed target product profiles for biomarker‐ or biosignature‐based diagnostics using point‐of‐care tests from easily accessible specimens such as urine or blood. Here we review and summarize progress made in the development of pathogen‐ and host‐based biomarkers for active TB diagnosis. We describe several unique patient populations that have posed challenges to development of a universal diagnostic TB biomarker, such as people living with HIV, extrapulmonary TB, and children. We also review additional limitations to widespread validation and utilization of published biomarkers. We conclude with proposed solutions to enhance TB diagnostic biomarker validation and uptake.
Graphical Abstract
In this review, B. Andrade and colleagues discuss progress and challenges in the development of diagnostic biomarkers for active tuberculosis and propose potential solutions to improve tuberculosis biomarker validation and implementation. |
|---|---|
| AbstractList | Tuberculosis (TB) is a leading cause of morbidity and mortality from a single infectious agent, despite being preventable and curable. Early and accurate diagnosis of active TB is critical to both enhance patient care, improve patient outcomes, and break
Mycobacterium tuberculosis
(
Mtb
) transmission cycles. In 2020 an estimated 9.9 million people fell ill from
Mtb
, but only a little over half (5.8 million) received an active TB diagnosis and treatment. The World Health Organization has proposed target product profiles for biomarker‐ or biosignature‐based diagnostics using point‐of‐care tests from easily accessible specimens such as urine or blood. Here we review and summarize progress made in the development of pathogen‐ and host‐based biomarkers for active TB diagnosis. We describe several unique patient populations that have posed challenges to development of a universal diagnostic TB biomarker, such as people living with HIV, extrapulmonary TB, and children. We also review additional limitations to widespread validation and utilization of published biomarkers. We conclude with proposed solutions to enhance TB diagnostic biomarker validation and uptake.
Graphical Abstract
In this review, B. Andrade and colleagues discuss progress and challenges in the development of diagnostic biomarkers for active tuberculosis and propose potential solutions to improve tuberculosis biomarker validation and implementation. Tuberculosis (TB) is a leading cause of morbidity and mortality from a single infectious agent, despite being preventable and curable. Early and accurate diagnosis of active TB is critical to both enhance patient care, improve patient outcomes, and break Mycobacterium tuberculosis (Mtb) transmission cycles. In 2020 an estimated 9.9 million people fell ill from Mtb, but only a little over half (5.8 million) received an active TB diagnosis and treatment. The World Health Organization has proposed target product profiles for biomarker- or biosignature-based diagnostics using point-of-care tests from easily accessible specimens such as urine or blood. Here we review and summarize progress made in the development of pathogen- and host-based biomarkers for active TB diagnosis. We describe several unique patient populations that have posed challenges to development of a universal diagnostic TB biomarker, such as people living with HIV, extrapulmonary TB, and children. We also review additional limitations to widespread validation and utilization of published biomarkers. We conclude with proposed solutions to enhance TB diagnostic biomarker validation and uptake. Tuberculosis (TB) is a leading cause of morbidity and mortality from a single infectious agent, despite being preventable and curable. Early and accurate diagnosis of active TB is critical to both enhance patient care, improve patient outcomes, and break Mycobacterium tuberculosis ( Mtb ) transmission cycles. In 2020 an estimated 9.9 million people fell ill from Mtb , but only a little over half (5.8 million) received an active TB diagnosis and treatment. The World Health Organization has proposed target product profiles for biomarker‐ or biosignature‐based diagnostics using point‐of‐care tests from easily accessible specimens such as urine or blood. Here we review and summarize progress made in the development of pathogen‐ and host‐based biomarkers for active TB diagnosis. We describe several unique patient populations that have posed challenges to development of a universal diagnostic TB biomarker, such as people living with HIV, extrapulmonary TB, and children. We also review additional limitations to widespread validation and utilization of published biomarkers. We conclude with proposed solutions to enhance TB diagnostic biomarker validation and uptake. Tuberculosis (TB) is a leading cause of morbidity and mortality from a single infectious agent, despite being preventable and curable. Early and accurate diagnosis of active TB is critical to both enhance patient care, improve patient outcomes, and break Mycobacterium tuberculosis (Mtb) transmission cycles. In 2020 an estimated 9.9 million people fell ill from Mtb, but only a little over half (5.8 million) received an active TB diagnosis and treatment. The World Health Organization has proposed target product profiles for biomarker- or biosignature-based diagnostics using point-of-care tests from easily accessible specimens such as urine or blood. Here we review and summarize progress made in the development of pathogen- and host-based biomarkers for active TB diagnosis. We describe several unique patient populations that have posed challenges to development of a universal diagnostic TB biomarker, such as people living with HIV, extrapulmonary TB, and children. We also review additional limitations to widespread validation and utilization of published biomarkers. We conclude with proposed solutions to enhance TB diagnostic biomarker validation and uptake.Tuberculosis (TB) is a leading cause of morbidity and mortality from a single infectious agent, despite being preventable and curable. Early and accurate diagnosis of active TB is critical to both enhance patient care, improve patient outcomes, and break Mycobacterium tuberculosis (Mtb) transmission cycles. In 2020 an estimated 9.9 million people fell ill from Mtb, but only a little over half (5.8 million) received an active TB diagnosis and treatment. The World Health Organization has proposed target product profiles for biomarker- or biosignature-based diagnostics using point-of-care tests from easily accessible specimens such as urine or blood. Here we review and summarize progress made in the development of pathogen- and host-based biomarkers for active TB diagnosis. We describe several unique patient populations that have posed challenges to development of a universal diagnostic TB biomarker, such as people living with HIV, extrapulmonary TB, and children. We also review additional limitations to widespread validation and utilization of published biomarkers. We conclude with proposed solutions to enhance TB diagnostic biomarker validation and uptake. Tuberculosis (TB) is a leading cause of morbidity and mortality from a single infectious agent, despite being preventable and curable. Early and accurate diagnosis of active TB is critical to both enhance patient care, improve patient outcomes, and break Mycobacterium tuberculosis (Mtb) transmission cycles. In 2020 an estimated 9.9 million people fell ill from Mtb, but only a little over half (5.8 million) received an active TB diagnosis and treatment. The World Health Organization has proposed target product profiles for biomarker- or biosignature-based diagnostics using point-of-care tests from easily accessible specimens such as urine or blood. Here we review and summarize progress made in the development of pathogen- and host-based biomarkers for active TB diagnosis. We describe several unique patient populations that have posed challenges to development of a universal diagnostic TB biomarker, such as people living with HIV, extrapulmonary TB, and children. We also review additional limitations to widespread validation and utilization of published biomarkers. We conclude with proposed solutions to enhance TB diagnostic biomarker validation and uptake. Abstract Tuberculosis (TB) is a leading cause of morbidity and mortality from a single infectious agent, despite being preventable and curable. Early and accurate diagnosis of active TB is critical to both enhance patient care, improve patient outcomes, and break Mycobacterium tuberculosis (Mtb) transmission cycles. In 2020 an estimated 9.9 million people fell ill from Mtb, but only a little over half (5.8 million) received an active TB diagnosis and treatment. The World Health Organization has proposed target product profiles for biomarker‐ or biosignature‐based diagnostics using point‐of‐care tests from easily accessible specimens such as urine or blood. Here we review and summarize progress made in the development of pathogen‐ and host‐based biomarkers for active TB diagnosis. We describe several unique patient populations that have posed challenges to development of a universal diagnostic TB biomarker, such as people living with HIV, extrapulmonary TB, and children. We also review additional limitations to widespread validation and utilization of published biomarkers. We conclude with proposed solutions to enhance TB diagnostic biomarker validation and uptake. Tuberculosis (TB) is a leading cause of morbidity and mortality from a single infectious agent, despite being preventable and curable. Early and accurate diagnosis of active TB is critical to both enhance patient care, improve patient outcomes, and break Mycobacterium tuberculosis (Mtb) transmission cycles. In 2020 an estimated 9.9 million people fell ill from Mtb, but only a little over half (5.8 million) received an active TB diagnosis and treatment. The World Health Organization has proposed target product profiles for biomarker‐ or biosignature‐based diagnostics using point‐of‐care tests from easily accessible specimens such as urine or blood. Here we review and summarize progress made in the development of pathogen‐ and host‐based biomarkers for active TB diagnosis. We describe several unique patient populations that have posed challenges to development of a universal diagnostic TB biomarker, such as people living with HIV, extrapulmonary TB, and children. We also review additional limitations to widespread validation and utilization of published biomarkers. We conclude with proposed solutions to enhance TB diagnostic biomarker validation and uptake. In this review, B. Andrade and colleagues discuss progress and challenges in the development of diagnostic biomarkers for active tuberculosis and propose potential solutions to improve tuberculosis biomarker validation and implementation. Tuberculosis (TB) is a leading cause of morbidity and mortality from a single infectious agent, despite being preventable and curable. Early and accurate diagnosis of active TB is critical to both enhance patient care, improve patient outcomes, and break Mycobacterium tuberculosis (Mtb) transmission cycles. In 2020 an estimated 9.9 million people fell ill from Mtb, but only a little over half (5.8 million) received an active TB diagnosis and treatment. The World Health Organization has proposed target product profiles for biomarker‐ or biosignature‐based diagnostics using point‐of‐care tests from easily accessible specimens such as urine or blood. Here we review and summarize progress made in the development of pathogen‐ and host‐based biomarkers for active TB diagnosis. We describe several unique patient populations that have posed challenges to development of a universal diagnostic TB biomarker, such as people living with HIV, extrapulmonary TB, and children. We also review additional limitations to widespread validation and utilization of published biomarkers. We conclude with proposed solutions to enhance TB diagnostic biomarker validation and uptake. In this review, B. Andrade and colleagues discuss progress and challenges in the development of diagnostic biomarkers for active tuberculosis and propose potential solutions to improve tuberculosis biomarker validation and implementation. |
| Author | Andrade, Bruno B Krishnan, Sonya Queiroz, Artur T L Salgame, Padmini Gupta, Amita Barreto‐Duarte, Beatriz Scriba, Thomas J Sterling, Timothy R Ellner, Jerrold J Nogueira, Betânia M F Araújo‐Pereira, Mariana |
| AuthorAffiliation | 11 South African Tuberculosis Vaccine Initiative and Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology University of Cape Town Cape Town South Africa 13 Curso de Medicina Faculdade de Tecnologia e Ciências (FTC) Salvador Brazil 9 Center of Data and Knowledge Integration for Health (CIDACS), Instituto Gonçalo Moniz Fundação Oswaldo Cruz Salvador Brazil 6 Programa de Pós‐Graduação em Clínica Médica Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil 1 Programa de Pós‐graduação em Ciências da Saúde Universidade Federal da Bahia Salvador Brazil 7 Laboratório de Inflamação e Biomarcadores, Instituto Gonçalo Moniz Fundação Oswaldo Cruz Salvador Brazil 14 Curso de Medicina Escola Bahiana de Medicina e Saúde Pública (EBMSP) Salvador Brazil 5 Curso de Medicina Universidade Salvador (UNIFACS) Salvador Brazil 8 Faculdade de Medicina Universidade Federal da Bahia Salvador Brazil 4 Division of Infectious Diseases, Department of Medicine Johns Ho |
| AuthorAffiliation_xml | – name: 5 Curso de Medicina Universidade Salvador (UNIFACS) Salvador Brazil – name: 1 Programa de Pós‐graduação em Ciências da Saúde Universidade Federal da Bahia Salvador Brazil – name: 3 Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative Salvador Brazil – name: 14 Curso de Medicina Escola Bahiana de Medicina e Saúde Pública (EBMSP) Salvador Brazil – name: 8 Faculdade de Medicina Universidade Federal da Bahia Salvador Brazil – name: 10 Department of Medicine, Centre for Emerging Pathogens Rutgers‐New Jersey Medical School Newark NJ USA – name: 2 Instituto Couto Maia Salvador Brazil – name: 6 Programa de Pós‐Graduação em Clínica Médica Universidade Federal do Rio de Janeiro Rio de Janeiro Brazil – name: 4 Division of Infectious Diseases, Department of Medicine Johns Hopkins University School of Medicine Baltimore MD USA – name: 11 South African Tuberculosis Vaccine Initiative and Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology University of Cape Town Cape Town South Africa – name: 7 Laboratório de Inflamação e Biomarcadores, Instituto Gonçalo Moniz Fundação Oswaldo Cruz Salvador Brazil – name: 9 Center of Data and Knowledge Integration for Health (CIDACS), Instituto Gonçalo Moniz Fundação Oswaldo Cruz Salvador Brazil – name: 12 Division of Infectious Diseases, Department of Medicine Vanderbilt University Medical Center Nashville TN USA – name: 13 Curso de Medicina Faculdade de Tecnologia e Ciências (FTC) Salvador Brazil |
| Author_xml | – sequence: 1 givenname: Betânia M F surname: Nogueira fullname: Nogueira, Betânia M F organization: Programa de Pós‐graduação em Ciências da Saúde, Universidade Federal da Bahia, Instituto Couto Maia, Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative – sequence: 2 givenname: Sonya surname: Krishnan fullname: Krishnan, Sonya organization: Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine – sequence: 3 givenname: Beatriz surname: Barreto‐Duarte fullname: Barreto‐Duarte, Beatriz organization: Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Curso de Medicina, Universidade Salvador (UNIFACS), Programa de Pós‐Graduação em Clínica Médica, Universidade Federal do Rio de Janeiro, Laboratório de Inflamação e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz – sequence: 4 givenname: Mariana surname: Araújo‐Pereira fullname: Araújo‐Pereira, Mariana organization: Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Laboratório de Inflamação e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Faculdade de Medicina, Universidade Federal da Bahia – sequence: 5 givenname: Artur T L surname: Queiroz fullname: Queiroz, Artur T L organization: Instituto Couto Maia, Center of Data and Knowledge Integration for Health (CIDACS), Instituto Gonçalo Moniz, Fundação Oswaldo Cruz – sequence: 6 givenname: Jerrold J surname: Ellner fullname: Ellner, Jerrold J organization: Department of Medicine, Centre for Emerging Pathogens, Rutgers‐New Jersey Medical School – sequence: 7 givenname: Padmini surname: Salgame fullname: Salgame, Padmini organization: Department of Medicine, Centre for Emerging Pathogens, Rutgers‐New Jersey Medical School – sequence: 8 givenname: Thomas J orcidid: 0000-0002-0641-1359 surname: Scriba fullname: Scriba, Thomas J organization: South African Tuberculosis Vaccine Initiative and Institute of Infectious Disease and Molecular Medicine, Division of Immunology, Department of Pathology, University of Cape Town – sequence: 9 givenname: Timothy R surname: Sterling fullname: Sterling, Timothy R organization: Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center – sequence: 10 givenname: Amita surname: Gupta fullname: Gupta, Amita organization: Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine – sequence: 11 givenname: Bruno B orcidid: 0000-0001-6833-3811 surname: Andrade fullname: Andrade, Bruno B email: bruno.andrade@fiocruz.br organization: Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Curso de Medicina, Universidade Salvador (UNIFACS), Laboratório de Inflamação e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Faculdade de Medicina, Universidade Federal da Bahia, Curso de Medicina, Faculdade de Tecnologia e Ciências (FTC), Curso de Medicina, Escola Bahiana de Medicina e Saúde Pública (EBMSP) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36314872$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUktv1DAYtFARfcCZG4rEhcu2ftvpAQmVFip1xQXOluN82Xpx4sVOivrv8TZlaSsBJ1v2zHwz9hyivSEOgNBrgo-JoIKeQN_3xxRTQjjW-hk6IEqoBZea7-32Su6jw5zXGEshiX6B9plkhGtFD9DFR29XQ8yjd1XjY2_Td0i56mKqrBv9DVTj1EByU4jZ59Nqk-IqQc6VHdrKXdsQYFhBfomedzZkeHW_HqFvF-dfzz4vrr58ujz7cLVwQtV60UEnGqItpTUVIDmmynIscMutk05JKLaEdJq0DbfaWQ1U1apjtBOi7oRmR-hy1m2jXZtN8sXwrYnWm7uDmFbGppIlgOGdo62oCWlxw7lljZVYEs6kbAlrFCta72etzdT00DoYxmTDI9HHN4O_Nqt4Y2pFNRaiCLy7F0jxxwR5NL3PDkKwA8QpG6oYllyVTAX69gl0Hac0lKcqKK4ow5puBd88dLSz8vu7CuBkBrgUc07Q7SAEm7tCmG0hzK4QhSGeMJwf7ejjNpIP_-CdzryfPsDt_8aY8-Vy-ZCMZ3IuvFKP9Cft3-b9Ai0_2kk |
| CitedBy_id | crossref_primary_10_1016_j_jcoa_2025_100204 crossref_primary_10_1186_s40001_024_02092_z crossref_primary_10_3390_math11214522 crossref_primary_10_3390_medicina61061096 crossref_primary_10_1016_j_ijtb_2025_05_006 crossref_primary_10_1128_spectrum_02236_24 crossref_primary_10_3389_fcimb_2025_1526740 crossref_primary_10_1016_j_ijtb_2025_06_022 crossref_primary_10_1016_j_ijid_2025_107875 crossref_primary_10_7554_eLife_102441_2 crossref_primary_10_7759_cureus_57311 crossref_primary_10_1002_jia2_26081 crossref_primary_10_3389_fimmu_2024_1419782 crossref_primary_10_1111_jcmm_70562 crossref_primary_10_3389_fgene_2023_1094099 crossref_primary_10_3389_fimmu_2023_1256558 crossref_primary_10_25259_IJMR_1281_23 crossref_primary_10_1183_13993003_00153_2024 crossref_primary_10_1007_s00604_024_06780_9 crossref_primary_10_1016_j_pbiomolbio_2023_03_001 crossref_primary_10_1186_s13019_025_03544_1 crossref_primary_10_4081_monaldi_2025_3433 crossref_primary_10_1016_j_micpath_2025_107843 crossref_primary_10_1155_2023_7829286 crossref_primary_10_3390_ijms241411385 crossref_primary_10_1186_s13568_025_01870_0 crossref_primary_10_3389_fcimb_2025_1567592 crossref_primary_10_3389_fgene_2024_1380828 crossref_primary_10_1371_journal_pone_0316648 crossref_primary_10_1186_s40001_024_01755_1 crossref_primary_10_1038_s41573_024_00897_5 crossref_primary_10_1038_s41591_024_02840_y crossref_primary_10_53879_id_62_07_15306 crossref_primary_10_1021_acs_jproteome_4c00989 crossref_primary_10_1109_JSEN_2024_3523750 crossref_primary_10_3389_fimmu_2024_1438989 crossref_primary_10_1016_j_bspc_2025_108642 crossref_primary_10_3390_neurolint17080119 crossref_primary_10_1089_sur_2022_357 crossref_primary_10_3389_fmicb_2024_1409552 crossref_primary_10_7759_cureus_55391 crossref_primary_10_1038_s41598_024_66113_x crossref_primary_10_1007_s11845_024_03799_y crossref_primary_10_1080_14737159_2024_2362165 crossref_primary_10_1134_S1070363224080255 crossref_primary_10_1080_07853890_2025_2527949 crossref_primary_10_1093_infdis_jiae365 crossref_primary_10_3389_fgene_2025_1544007 crossref_primary_10_3389_fcimb_2025_1595076 crossref_primary_10_1002_ila2_70017 crossref_primary_10_7554_eLife_102441 crossref_primary_10_1007_s11306_024_02194_z crossref_primary_10_1016_j_ijid_2024_106984 |
| Cites_doi | 10.2217/bmm-2017-0141 10.1016/j.puhe.2016.03.033 10.1136/thoraxjnl-2018-212557 10.1183/13993003.00526-2021 10.1016/j.cyto.2019.154773 10.1007/s15010-014-0602-8 10.1177/1178636118813367 10.1371/journal.pone.0162220 10.1371/journal.pone.0092308 10.3389/fmicb.2018.00602 10.1371/journal.pone.0147933 10.1016/S2214-109X(20)30288-6 10.1016/j.ebiom.2015.07.039 10.1016/j.tube.2016.11.006 10.1016/S2213-2600(16)00048-5 10.1016/S1473-3099(11)70251-1 10.3390/tropicalmed4020057 10.1038/s41564-019-0380-2 10.1093/cid/cis732 10.1093/infdis/jiz639 10.1183/13993003.01886-2019 10.1172/jci.insight.137427 10.3389/fcimb.2022.792617 10.1186/1471-2334-13-506 10.1016/S1473-3099(20)30914-2 10.1128/jcm.00155-22 10.1016/S1473-3099(21)00387-X 10.1093/cid/ciaa1402 10.1016/j.ebiom.2021.103787 10.1093/bib/bby051 10.1001/jamanetworkopen.2018.7617 10.1161/HYPERTENSIONAHA.120.16340 10.1128/JCM.01338-18 10.1097/AOG.0000000000003890 10.1136/thoraxjnl-2015-207999 10.1093/cid/ciz1070 10.1186/s12879-020-05243-9 10.1097/QAI.0000000000001298 10.1038/s41598-019-53086-5 10.1016/S1473-3099(20)30928-2 10.1016/S0140-6736(15)01316-1 10.1056/NEJMoa1303657 10.1183/13993003.00655-2019 10.1186/s12913-020-4997-x 10.1038/s41598-018-20855-7 10.3389/fpubh.2021.757133 10.1371/journal.pone.0218890 10.1111/j.1600-0897.2010.00836.x 10.1128/JCM.00467-17 10.1016/j.tibtech.2004.06.005 10.3389/fmicb.2019.02789 10.1016/j.mib.2017.09.013 10.1016/S0140-6736(07)60284-0 10.3389/fimmu.2020.00419 10.1093/cid/ciab839 10.1371/journal.pone.0237574 10.18632/oncotarget.11420 10.1093/cid/civ1223 10.1016/S1473-3099(18)30111-7 10.1016/j.tube.2018.09.009 10.1038/s41598-017-05057-x 10.1183/13993003.01718-2020 10.1016/S1473-3099(17)30691-6 10.1056/NEJMp2118145 10.1016/j.jtho.2021.01.1616 10.1016/j.tube.2019.04.002 10.1371/journal.pone.0016425 10.1016/j.ijid.2021.09.010 10.1183/13993003.02121-2015 10.1016/j.ijid.2020.08.019 10.1371/journal.pmed.1002152 10.1038/s41598-020-60753-5 10.1038/s41598-020-60669-0 10.2147/IDR.S345619 10.1371/journal.pone.0256883 10.3892/mmr.2015.4262 10.1038/s41598-020-75513-8 10.1038/s43856-022-00086-8 10.3389/fimmu.2021.676980 10.3389/fimmu.2019.01968 10.1038/s41467-018-07635-7 10.1183/09031936.00007814 10.1016/S1473-3099(14)70884-9 10.1093/infdis/jis009 10.1371/journal.pone.0098938 10.1128/IAI.00649-19 10.1016/j.jctube.2021.100284 10.1056/NEJMcp2108501 10.1016/S2214-109X(21)00045-0 10.1371/journal.pone.0126018 10.3389/fmicb.2019.01441 10.1016/j.tube.2017.08.010 10.1093/cid/civ611 10.1093/cid/ciaa1083 10.1164/rccm.201904-0772OC 10.1016/j.ijmyco.2014.04.003 10.1371/journal.pmed.1001538 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 2022 The Authors. Published under the terms of the CC BY 4.0 license. 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2022 – notice: 2022 The Authors. Published under the terms of the CC BY 4.0 license. – notice: 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 8AO 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU COVID DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.15252/emmm.202114088 |
| DatabaseName | Springer Nature OA Free Journals Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Coronavirus Research Database ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Biological Science Database ProQuest Databases ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE CrossRef MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: PIMPY name: Publicly Available Content Database (ProQuest) url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| DocumentTitleAlternate | Betânia M F Nogueira et al |
| EISSN | 1757-4684 |
| EndPage | n/a |
| ExternalDocumentID | oai_doaj_org_article_4fc2d5911d0b44a3ba60614366d13b73 PMC9728055 36314872 10_15252_emmm_202114088 EMMM202114088 |
| Genre | reviewArticle Review Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: CRDF Global (CRDF) grantid: DAA3‐19‐65678‐1 funderid: 10.13039/100004419 – fundername: Fundação Oswaldo Cruz (FIOCRUZ) grantid: Intramural Research Program funderid: 10.13039/501100006507 – fundername: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) funderid: 10.13039/501100003593 – fundername: HHS ¦ National Institutes of Health (NIH) grantid: T32 AI007291‐27 funderid: 10.13039/100000002 – fundername: Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) – fundername: CRDF Global (CRDF) funderid: DAA3‐19‐65678‐1 – fundername: HHS ¦ National Institutes of Health (NIH) funderid: T32 AI007291‐27 – fundername: Fundação Oswaldo Cruz (FIOCRUZ) funderid: Intramural Research Program – fundername: NIAID NIH HHS grantid: T32 AI007291 – fundername: ; – fundername: ; grantid: Intramural Research Program – fundername: ; grantid: T32 AI007291‐27 – fundername: ; grantid: DAA3‐19‐65678‐1 |
| GroupedDBID | --- 0R~ 1OC 24P 4.4 53G 5DZ 5GY 5VS 7X7 8-0 8-1 8AO 8FE 8FH 8FI 8FJ AAJSJ AAMMB AASML AAZKR ABOCM ABUWG ACCMX ACGFO ACGFS ACPRK ACXQS ADBBV ADKYN ADZMN AEFGJ AEGXH AENEX AFBPY AFKRA AGXDD AHMBA AIAGR AIDQK AIDYY ALAGY ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BTFSW BVXVI C6C CCPQU D-9 DIK DU5 EBD EBLON EBS EMOBN F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HK~ HMCUK HYE HZ~ IAO IHR KQ8 LH4 LK8 M48 M7P NAO NNB O9- OIG OK1 OVD P2P PHGZM PHGZT PIMPY PQGLB PQQKQ PROAC RHI RNS ROL RPM SV3 TEORI UKHRP WIN XV2 AAHHS ABJNI ACCFJ ADPDF ADZOD AEEZP AEQDE AIWBW AJBDE M~E OVEED RHF AAYXX AFFHD AJAOE CITATION CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AZQEC COVID DWQXO GNUQQ K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c5798-fef5b18a22925e64027a4050d4ac6c76e31456c81db4a8ca8e2797f32f559f583 |
| IEDL.DBID | 24P |
| ISICitedReferencesCount | 60 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000876419000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1757-4676 1757-4684 |
| IngestDate | Mon Nov 10 04:32:09 EST 2025 Tue Nov 04 02:07:03 EST 2025 Sun Sep 28 02:21:20 EDT 2025 Sat Nov 29 15:00:18 EST 2025 Thu Apr 03 07:00:01 EDT 2025 Tue Nov 18 22:14:48 EST 2025 Sat Nov 29 03:08:56 EST 2025 Wed Jan 22 16:22:26 EST 2025 Tue Aug 12 01:11:07 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | biomarkers diagnostic biomarkers active TB tuberculosis |
| Language | English |
| License | Attribution 2022 The Authors. Published under the terms of the CC BY 4.0 license. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5798-fef5b18a22925e64027a4050d4ac6c76e31456c81db4a8ca8e2797f32f559f583 |
| Notes | See the Glossary for abbreviations used in this article. These authors contributed equally to this work ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-0641-1359 0000-0001-6833-3811 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.15252%2Femmm.202114088 |
| PMID | 36314872 |
| PQID | 2747230825 |
| PQPubID | 866378 |
| PageCount | 13 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_4fc2d5911d0b44a3ba60614366d13b73 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9728055 proquest_miscellaneous_2730647314 proquest_journals_2747230825 pubmed_primary_36314872 crossref_primary_10_15252_emmm_202114088 crossref_citationtrail_10_15252_emmm_202114088 wiley_primary_10_15252_emmm_202114088_EMMM202114088 springer_journals_10_15252_emmm_202114088 |
| PublicationCentury | 2000 |
| PublicationDate | 7 December 2022 |
| PublicationDateYYYYMMDD | 2022-12-07 |
| PublicationDate_xml | – month: 12 year: 2022 text: 7 December 2022 day: 07 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England – name: Frankfurt – name: Hoboken |
| PublicationTitle | EMBO molecular medicine |
| PublicationTitleAbbrev | EMBO Mol Med |
| PublicationTitleAlternate | EMBO Mol Med |
| PublicationYear | 2022 |
| Publisher | Nature Publishing Group UK EMBO Press John Wiley and Sons Inc Springer Nature |
| Publisher_xml | – name: Nature Publishing Group UK – name: EMBO Press – name: John Wiley and Sons Inc – name: Springer Nature |
| References | 2004; 22 2020; 20 2019; 10 2019; 14 2016; 387 2020; 15 2014; 370 2020; 99 2020; 11 2020; 10 2022; 22 2012; 12 2021; 74 2021; 73 2019; 200 2017; 75 2018; 9 2018; 8 2021; 77 2019; 20 2014; 14 2020; 88 2019; 9 2019; 4 2021; 45 2019; 2 2018; 108 2020; 36 2021; 385 2016a; 47 2011; 6 2014; 44 2016; 13 2016; 11 2014; 42 2021; 58 2016; 4 2018; 18 2016; 7 2015; 61 2017; 55 2018; 113 2022; 12 2022; 15 2022; 2 2018; 11 2021; 25 2017; 7 2021; 21 2019; 54 2016; 71 2020; 56 2020; 55 2012; 205 2012; 55 2010; 63 2019; 123 2020; 8 2020; 7 2020; 5 2014; 3 2021; 112 2013; 10 2017; 39 2013; 13 2019; 116 2022; 75 2020; 135 2014; 9 2011; 163 2015; 2 2021; 9 2015; 12 2007; 369 2016b; 11 2019; 74 2011 2015; 10 2021d 2021c 2021b 2021a 2020; 221 2022; 386 2021; 16 2021; 12 2022; 60 2021 2017; 11 2020; 71 2019 2016; 62 2016 2016; 138 2014 2013 2018; 56 2017; 102 e_1_2_8_49_1 e_1_2_8_68_1 White E (e_1_2_8_101_1) 2011; 163 WHO (e_1_2_8_107_1) 2021 e_1_2_8_5_1 e_1_2_8_9_1 e_1_2_8_22_1 e_1_2_8_45_1 e_1_2_8_64_1 e_1_2_8_87_1 e_1_2_8_113_1 e_1_2_8_41_1 e_1_2_8_60_1 e_1_2_8_83_1 e_1_2_8_19_1 e_1_2_8_109_1 e_1_2_8_15_1 e_1_2_8_38_1 e_1_2_8_57_1 e_1_2_8_91_1 e_1_2_8_95_1 Costantini L (e_1_2_8_18_1) 2020; 7 e_1_2_8_99_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_53_1 e_1_2_8_76_1 Engel N (e_1_2_8_26_1) 2019 e_1_2_8_30_1 e_1_2_8_72_1 e_1_2_8_25_1 WHO (e_1_2_8_108_1) 2021 Kohli M (e_1_2_8_48_1) 2018; 8 e_1_2_8_2_1 e_1_2_8_110_1 e_1_2_8_6_1 e_1_2_8_21_1 e_1_2_8_67_1 e_1_2_8_44_1 e_1_2_8_86_1 e_1_2_8_63_1 e_1_2_8_40_1 e_1_2_8_82_1 e_1_2_8_14_1 e_1_2_8_37_1 e_1_2_8_79_1 e_1_2_8_94_1 e_1_2_8_90_1 e_1_2_8_98_1 e_1_2_8_10_1 e_1_2_8_56_1 e_1_2_8_33_1 e_1_2_8_75_1 e_1_2_8_52_1 e_1_2_8_28_1 e_1_2_8_24_1 e_1_2_8_47_1 e_1_2_8_3_1 e_1_2_8_81_1 e_1_2_8_111_1 e_1_2_8_7_1 WHO (e_1_2_8_105_1) 2021 e_1_2_8_20_1 e_1_2_8_43_1 e_1_2_8_66_1 e_1_2_8_89_1 e_1_2_8_62_1 e_1_2_8_85_1 e_1_2_8_17_1 e_1_2_8_13_1 e_1_2_8_36_1 e_1_2_8_59_1 FDA‐NIH Biomarker Working Group (e_1_2_8_29_1) 2016 e_1_2_8_70_1 e_1_2_8_97_1 WHO (e_1_2_8_104_1) 2014 e_1_2_8_32_1 e_1_2_8_55_1 e_1_2_8_78_1 e_1_2_8_51_1 e_1_2_8_74_1 e_1_2_8_93_1 e_1_2_8_46_1 Conde R (e_1_2_8_16_1) 2021; 45 e_1_2_8_27_1 e_1_2_8_69_1 WHO (e_1_2_8_106_1) 2021 e_1_2_8_80_1 e_1_2_8_4_1 e_1_2_8_8_1 e_1_2_8_42_1 e_1_2_8_88_1 e_1_2_8_23_1 e_1_2_8_65_1 e_1_2_8_84_1 e_1_2_8_112_1 e_1_2_8_61_1 e_1_2_8_39_1 World Health Organization (WHO) (e_1_2_8_102_1) 2011 e_1_2_8_35_1 e_1_2_8_58_1 e_1_2_8_92_1 e_1_2_8_96_1 e_1_2_8_100_1 Nicol MP (e_1_2_8_71_1) 2020; 36 e_1_2_8_31_1 e_1_2_8_77_1 e_1_2_8_12_1 e_1_2_8_54_1 e_1_2_8_73_1 WHO (e_1_2_8_103_1) 2013 e_1_2_8_50_1 |
| References_xml | – year: 2011 – volume: 8 year: 2018 article-title: Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance publication-title: Cochrane Database Syst Rev – volume: 47 start-page: 1873 year: 2016a end-page: 1876 article-title: A 380‐gene meta‐signature of active tuberculosis compared with healthy controls publication-title: Eur Respir J – volume: 75 start-page: 128 year: 2017 end-page: 136 article-title: Effect of pregnancy on interferon gamma release assay and tuberculin skin test detection of latent TB infection among HIV‐infected women in a high burden setting publication-title: J Acquir Immune Defic Syndr – volume: 135 start-page: 1444 year: 2020 end-page: 1453 article-title: Tuberculosis in pregnancy publication-title: Obstet Gynecol – volume: 60 year: 2022 article-title: Diagnostic accuracy of the truenat MTB plus assay and comparison with the Xpert MTB/RIF assay to detect tuberculosis among hospital outpatients in Cameroon publication-title: J Clin Microbiol – volume: 11 start-page: 419 year: 2020 article-title: Matrix metalloproteinases and tissue inhibitors of metalloproteinases are potential biomarkers of pulmonary and extra‐pulmonary tuberculosis publication-title: Front Immunol – volume: 9 start-page: 5208 year: 2018 article-title: Metabolite changes in blood predict the onset of tuberculosis publication-title: Nat Commun – volume: 9 year: 2014 article-title: Pregnancy differentially impacts performance of latent tuberculosis diagnostics in a high‐burden setting publication-title: PLoS One – volume: 62 start-page: 995 year: 2016 end-page: 1001 article-title: Xpert MTB/RIF results in patients with previous tuberculosis: can we distinguish true from false positive results? publication-title: Clin Infect Dis – volume: 73 start-page: e830 year: 2021 end-page: e841 article-title: Subclinical tuberculosis disease‐a review and analysis of prevalence surveys to inform definitions, burden, associations, and screening methodology publication-title: Clin Infect Dis – volume: 4 start-page: 213 year: 2016 end-page: 224 article-title: Genome‐wide expression for diagnosis of pulmonary tuberculosis: a multicohort analysis publication-title: Lancet Respir Med – volume: 163 start-page: 143 year: 2011 end-page: 161 article-title: Measurement error in biomarkers: sources, assessment, and impact on studies publication-title: IARC Sci Publ – volume: 221 start-page: 1647 year: 2020 end-page: 1658 article-title: Transcriptomic profiles of confirmed pediatric tuberculosis patients and household contacts identifies active tuberculosis, infection, and treatment response among Indian children publication-title: J Infect Dis – volume: 11 year: 2016b article-title: The transcriptional signature of active tuberculosis reflects symptom status in extra‐pulmonary and pulmonary tuberculosis publication-title: PLoS One – volume: 54 year: 2019 article-title: The global prevalence of latent tuberculosis: a systematic review and meta‐analysis publication-title: Eur Respir J – volume: 61 start-page: S155 year: 2015 end-page: S159 article-title: RePORT International: advancing tuberculosis biomarker research through global collaboration publication-title: Clin Infect Dis – year: 2014 – volume: 16 start-page: 537 year: 2021 end-page: 545 article-title: Biomarker discovery and validation: statistical considerations publication-title: J Thorac Oncol – volume: 387 start-page: 2312 year: 2016 end-page: 2322 article-title: A blood RNA signature for tuberculosis disease risk: a prospective cohort study publication-title: Lancet – volume: 10 year: 2015 article-title: Differential microRNA expression in human macrophages with infection of Beijing/W and non‐Beijing/W strain types publication-title: PLoS One – volume: 8 start-page: 2675 year: 2018 article-title: Africa‐wide evaluation of host biomarkers in QuantiFERON supernatants for the diagnosis of pulmonary tuberculosis publication-title: Sci Rep – volume: 16 year: 2021 article-title: Public investments in the development of GeneXpert molecular diagnostic technology publication-title: PLoS One – volume: 7 start-page: 57581 year: 2016 end-page: 57592 article-title: Identification of novel host biomarkers in plasma as candidates for the immunodiagnosis of tuberculosis disease and monitoring of tuberculosis treatment response publication-title: Oncotarget – volume: 138 start-page: 101 year: 2016 end-page: 107 article-title: High proportion of extrapulmonary tuberculosis in a low prevalence setting: a retrospective cohort study publication-title: Public Health – volume: 20 start-page: 543 year: 2020 article-title: Impact of GeneXpert MTB/RIF® on treatment initiation and outcomes of RIF‐resistant and RIF‐susceptible TB patients in Vladimir TB dispensary, Russia publication-title: BMC Infect Dis – year: 2021d – volume: 99 start-page: 473 year: 2020 end-page: 481 article-title: Host urine immunological biomarkers as potential candidates for the diagnosis of tuberculosis publication-title: Int J Infect Dis – volume: 102 start-page: 55 year: 2017 end-page: 67 article-title: Advances in basic and translational tuberculosis research: proceedings of the first meeting of RePORT international publication-title: Tuberculosis (Edinb) – volume: 12 start-page: 6561 year: 2015 end-page: 6567 article-title: MicroRNA signatures from multidrug‐resistant publication-title: Mol Med Rep – volume: 56 year: 2020 article-title: The potential impact of COVID‐19‐related disruption on tuberculosis burden publication-title: Eur Respir J – year: 2021a – volume: 75 year: 2022 article-title: Plasma host protein biomarkers correlating with increasing infection activity prior to tuberculosis diagnosis in people living with HIV publication-title: EBioMedicine – volume: 10 year: 2020 article-title: Integration of metabolomics and transcriptomics reveals novel biomarkers in the blood for tuberculosis diagnosis in children publication-title: Sci Rep – volume: 44 start-page: 435 year: 2014 end-page: 446 article-title: Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a systematic review and meta‐analysis publication-title: Eur Respir J – year: 2019 – volume: 20 start-page: 1795 year: 2019 end-page: 1811 article-title: Review of applications of high‐throughput sequencing in personalized medicine: barriers and facilitators of future progress in research and clinical application publication-title: Brief Bioinform – volume: 9 year: 2021 article-title: The value of FujiLAM in the diagnosis of tuberculosis: a systematic review and meta‐analysis publication-title: Front Public Health – volume: 113 start-page: 153 year: 2018 end-page: 162 article-title: Building capacity for advances in tuberculosis research; proceedings of the third RePORT international meeting publication-title: Tuberculosis (Edinb) – volume: 58 year: 2021 article-title: A prospective multicentre diagnostic accuracy study for the Truenat tuberculosis assays publication-title: Eur Respir J – volume: 71 start-page: 785 year: 2016 end-page: 794 article-title: Diagnostic performance of a seven‐marker serum protein biosignature for the diagnosis of active TB disease in African primary healthcare clinic attendees with signs and symptoms suggestive of TB publication-title: Thorax – year: 2016 – volume: 10 start-page: 1968 year: 2019 article-title: Lipoarabinomannan in active and passive protection against tuberculosis publication-title: Front Immunol – volume: 13 start-page: 506 year: 2013 article-title: The discovery and identification of a candidate proteomic biomarker of active tuberculosis publication-title: BMC Infect Dis – volume: 73 start-page: e3555 year: 2021 end-page: e3562 article-title: Effects of pregnancy and isoniazid preventive therapy on interferon gamma response assays in women with HIV publication-title: Clin Infect Dis – volume: 39 start-page: 64 year: 2017 end-page: 72 article-title: Systems proteomics approaches to study bacterial pathogens: application to publication-title: Curr Opin Microbiol – volume: 4 start-page: 748 year: 2019 end-page: 758 article-title: A systematic review of biomarkers to detect active tuberculosis publication-title: Nat Microbiol – volume: 369 start-page: 2042 year: 2007 end-page: 2049 article-title: Diagnosis of smear‐negative pulmonary tuberculosis in people with HIV infection or AIDS in resource‐constrained settings: informing urgent policy changes publication-title: Lancet – volume: 386 start-page: 1490 year: 2022 end-page: 1493 article-title: Covid‐19's devastating effect on tuberculosis care – a path to recovery publication-title: N Engl J Med – volume: 10 start-page: 3825 year: 2020 article-title: Identification of serum biomarkers for active pulmonary tuberculosis using a targeted metabolomics approach publication-title: Sci Rep – volume: 56 year: 2018 article-title: A novel sensitive immunoassay targeting the 5‐methylthio‐d‐xylofuranose‐lipoarabinomannan epitope meets the WHO's performance target for tuberculosis diagnosis publication-title: J Clin Microbiol – volume: 18 start-page: e199 year: 2018 end-page: e210 article-title: Tuberculosis: advances and challenges in development of new diagnostics and biomarkers publication-title: Lancet Infect Dis – volume: 11 start-page: 1017 year: 2017 end-page: 1029 article-title: The role of metabolomics in tuberculosis treatment research publication-title: Biomark Med – volume: 55 start-page: 1532 year: 2012 end-page: 1549 article-title: Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps publication-title: Clin Infect Dis – volume: 12 year: 2021 article-title: Integrative multi‐omics reveals serum markers of tuberculosis in advanced HIV publication-title: Front Immunol – volume: 55 start-page: 3057 year: 2017 end-page: 3071 article-title: Discovery and validation of a six‐marker serum protein signature for the diagnosis of active pulmonary tuberculosis publication-title: J Clin Microbiol – volume: 112 start-page: 205 year: 2021 end-page: 211 article-title: Stages of pregnancy and HIV affect diagnosis of tuberculosis infection and (MTB)‐induced immune response: findings from PRACHITi, a cohort study in Pune, India publication-title: Int J Infect Dis – year: 2013 – volume: 11 year: 2018 article-title: Human immunodeficiency virus and tuberculosis coinfection in a tertiary hospital in southern Brazil: clinical profile and outcomes publication-title: Microbiol Insights – volume: 12 start-page: 201 year: 2012 end-page: 209 article-title: Diagnostic accuracy of a low‐cost, urine antigen, point‐of‐care screening assay for HIV‐associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study publication-title: Lancet Infect Dis – volume: 74 start-page: 2136 year: 2021 end-page: 2141 article-title: Diagnostic accuracy of the Cepheid 3‐gene host response fingerstick blood test in a prospective, multi‐site study: interim results publication-title: Clin Infect Dis – volume: 42 start-page: 649 year: 2014 end-page: 654 article-title: Extra‐pulmonary tuberculosis: a biomarker analysis publication-title: Infection – year: 2021c – volume: 8 start-page: e1132 year: 2020 end-page: e1141 article-title: Potential impact of the COVID‐19 pandemic on HIV, tuberculosis, and malaria in low‐income and middle‐income countries: a modelling study publication-title: Lancet Glob Health – volume: 13 year: 2016 article-title: The global burden of latent tuberculosis infection: a re‐estimation using mathematical modelling publication-title: PLoS Med – volume: 15 year: 2020 article-title: Performance of diagnostic and predictive host blood transcriptomic signatures for Tuberculosis disease: a systematic review and meta‐analysis publication-title: PLoS One – volume: 10 start-page: 1441 year: 2019 article-title: Detection of tuberculosis recurrence, diagnosis and treatment response by a blood transcriptomic risk signature in HIV‐infected persons on antiretroviral therapy publication-title: Front Microbiol – volume: 370 start-page: 1712 year: 2014 end-page: 1723 article-title: Diagnosis of childhood tuberculosis and host RNA expression in Africa publication-title: N Engl J Med – year: 2021 – volume: 12 year: 2022 article-title: Using omics to study leprosy, tuberculosis, and other mycobacterial diseases publication-title: Front Cell Infect Microbiol – volume: 123 year: 2019 article-title: Plasma levels of C‐reactive protein, matrix metalloproteinase‐7 and lipopolysaccharide‐binding protein distinguish active pulmonary or extrapulmonary tuberculosis from uninfected controls in children publication-title: Cytokine – volume: 21 start-page: 366 year: 2021 end-page: 375 article-title: Transcriptomic signatures for diagnosing tuberculosis in clinical practice: a prospective, multicentre cohort study publication-title: Lancet Infect Dis – volume: 3 start-page: 205 year: 2014 end-page: 210 article-title: Evaluation of the Indian TrueNAT micro RT‐PCR device with GeneXpert for case detection of pulmonary tuberculosis publication-title: Int J Mycobacteriol – volume: 45 start-page: 654 year: 2021 end-page: 664 article-title: Discovery of serum biomarkers for diagnosis of tuberculosis by NMR metabolomics including cross‐validation with a second cohort publication-title: Biom J – volume: 4 start-page: E57 year: 2019 article-title: An observational case‐control study to determine human immunodeficiency virus and host factor influence on biomarker distribution and serodiagnostic potential in adult pulmonary tuberculosis publication-title: Trop Med Infect Dis – volume: 18 start-page: 76 year: 2018 end-page: 84 article-title: Xpert MTB/RIF Ultra for detection of and rifampicin resistance: a prospective multicentre diagnostic accuracy study publication-title: Lancet Infect Dis – volume: 10 year: 2013 article-title: Detection of tuberculosis in HIV‐infected and ‐uninfected African adults using whole blood RNA expression signatures: a case‐control study publication-title: PLoS Med – volume: 2 start-page: 26 year: 2022 article-title: Prospective multicentre head‐to‐head validation of host blood transcriptomic biomarkers for pulmonary tuberculosis by real‐time PCR publication-title: Commun Med (Lond) – volume: 14 start-page: 931 year: 2014 end-page: 938 article-title: Assessment of the novel T‐cell activation marker‐tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof‐of‐concept study publication-title: Lancet Infect Dis – volume: 9 start-page: e841 year: 2021 end-page: e853 article-title: Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study publication-title: Lancet Glob Health – volume: 25 year: 2021 article-title: A systematic review of potential screening biomarkers for active TB disease publication-title: J Clin Tuberc Other Mycobact Dis – volume: 7 year: 2020 article-title: Long‐term GeneXpert positivity after treatment for pulmonary tuberculosis publication-title: Eur J Case Rep Intern Med – volume: 2 year: 2019 article-title: Factors associated with sputum culture‐negative vs culture‐positive diagnosis of pulmonary tuberculosis publication-title: JAMA Netw Open – volume: 21 start-page: 354 year: 2021 end-page: 365 article-title: Biomarker‐guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial publication-title: Lancet Infect Dis – volume: 36 start-page: 52 year: 2020 end-page: 56 article-title: Advances in the diagnosis of pulmonary tuberculosis in children publication-title: Paediatr Respir Rev – volume: 2 start-page: 1160 year: 2015 end-page: 1168 article-title: Host protein biomarkers identify active tuberculosis in HIV uninfected and co‐infected individuals publication-title: EBioMedicine – volume: 14 year: 2019 article-title: Rapid, point‐of‐care diagnosis of tuberculosis with novel Truenat assay: cost‐effectiveness analysis for India's public sector publication-title: PLoS One – volume: 11 year: 2016 article-title: Characteristics of patients with smear‐negative pulmonary tuberculosis (TB) in a region with high TB and HIV prevalence publication-title: PLoS One – volume: 71 start-page: 1905 year: 2020 end-page: 1911 article-title: Differential expression of activation markers by ‐specific CD4 T cell distinguishes extrapulmonary from pulmonary tuberculosis and latent infection publication-title: Clin Infect Dis – volume: 9 year: 2014 article-title: The human antibody response to the surface of publication-title: PLoS One – volume: 88 year: 2020 article-title: Unraveling the role of microRNAs in infection and disease: advances and pitfalls publication-title: Infect Immun – volume: 200 start-page: 1531 year: 2019 end-page: 1538 article-title: Tuberculosis diagnosis in children using Xpert ultra on different respiratory specimens publication-title: Am J Respir Crit Care Med – volume: 22 start-page: 411 year: 2004 end-page: 416 article-title: Biomarker discovery and validation: technologies and integrative approaches publication-title: Trends Biotechnol – volume: 20 start-page: 162 year: 2020 article-title: Challenges with scale‐up of GeneXpert MTB/RIF® in Uganda: a health systems perspective publication-title: BMC Health Serv Res – volume: 108 start-page: 26 year: 2018 end-page: 34 article-title: Screening and identification of four serum miRNAs as novel potential biomarkers for cured pulmonary tuberculosis publication-title: Tuberculosis (Edinb) – volume: 15 start-page: 285 year: 2022 end-page: 294 article-title: The role of GeneXpert MTB/RIF in reducing treatment delay among multidrug resistance tuberculosis patients: a propensity score matched analysis publication-title: Infect Drug Resist – volume: 77 start-page: 1029 year: 2021 end-page: 1035 article-title: Data sharing under the general data protection regulation: time to harmonize law and research ethics? publication-title: Hypertension – volume: 9 start-page: 16587 year: 2019 article-title: A comparative evaluation of the new Genexpert MTB/RIF ultra and other rapid diagnostic assays for detecting tuberculosis in pulmonary and extra pulmonary specimens publication-title: Sci Rep – volume: 385 start-page: 2271 year: 2021 end-page: 2280 article-title: Latent tuberculosis infection publication-title: N Engl J Med – volume: 74 start-page: 1161 year: 2019 end-page: 1167 article-title: Biomarkers of iron metabolism facilitate clinical diagnosis in infection publication-title: Thorax – volume: 10 start-page: 2789 year: 2019 article-title: Immune biomarkers for diagnosis and treatment monitoring of tuberculosis: current developments and future prospects publication-title: Front Microbiol – volume: 7 start-page: 5839 year: 2017 article-title: Novel transcriptional signatures for sputum‐independent diagnostics of tuberculosis in children publication-title: Sci Rep – volume: 10 start-page: 3844 year: 2020 article-title: Serum proteomics of active tuberculosis patients and contacts reveals unique processes activated during infection publication-title: Sci Rep – year: 2021b – volume: 63 start-page: 425 year: 2010 end-page: 433 article-title: The immune system in pregnancy: a unique complexity publication-title: Am J Reprod Immunol – volume: 6 year: 2011 article-title: Validation of the ALS assay in adult patients with culture confirmed pulmonary tuberculosis publication-title: PLoS One – volume: 205 start-page: S216 year: 2012 end-page: S227 article-title: Prevention, diagnosis, and treatment of tuberculosis in children and mothers: evidence for action for maternal, neonatal, and child health services publication-title: J Infect Dis – volume: 116 start-page: 37 year: 2019 end-page: 43 article-title: Host and MTB genome encoded miRNA markers for diagnosis of tuberculosis publication-title: Tuberculosis (Edinb) – volume: 55 year: 2020 article-title: Increased risk of active tuberculosis during pregnancy and postpartum: a register‐based cohort study in Sweden publication-title: Eur Respir J – volume: 9 start-page: 602 year: 2018 article-title: miRNAs in tuberculosis: new avenues for diagnosis and host‐directed therapy publication-title: Front Microbiol – volume: 22 start-page: 507 year: 2022 end-page: 518 article-title: Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta‐analysis publication-title: Lancet Infect Dis – volume: 5 year: 2020 article-title: Comprehensive plasma proteomic profiling reveals biomarkers for active tuberculosis publication-title: JCI Insight – ident: e_1_2_8_56_1 doi: 10.2217/bmm-2017-0141 – ident: e_1_2_8_83_1 doi: 10.1016/j.puhe.2016.03.033 – ident: e_1_2_8_19_1 doi: 10.1136/thoraxjnl-2018-212557 – ident: e_1_2_8_76_1 doi: 10.1183/13993003.00526-2021 – ident: e_1_2_8_4_1 doi: 10.1016/j.cyto.2019.154773 – ident: e_1_2_8_30_1 doi: 10.1007/s15010-014-0602-8 – ident: e_1_2_8_92_1 doi: 10.1177/1178636118813367 – ident: e_1_2_8_9_1 doi: 10.1371/journal.pone.0162220 – ident: e_1_2_8_60_1 doi: 10.1371/journal.pone.0092308 – ident: e_1_2_8_82_1 doi: 10.3389/fmicb.2018.00602 – volume-title: Global tuberculosis report year: 2021 ident: e_1_2_8_107_1 – ident: e_1_2_8_10_1 doi: 10.1371/journal.pone.0147933 – ident: e_1_2_8_41_1 doi: 10.1016/S2214-109X(20)30288-6 – ident: e_1_2_8_2_1 doi: 10.1016/j.ebiom.2015.07.039 – ident: e_1_2_8_33_1 doi: 10.1016/j.tube.2016.11.006 – ident: e_1_2_8_90_1 doi: 10.1016/S2213-2600(16)00048-5 – ident: e_1_2_8_51_1 doi: 10.1016/S1473-3099(11)70251-1 – ident: e_1_2_8_65_1 doi: 10.3390/tropicalmed4020057 – volume-title: Impact of the COVID‐19 pandemic on TB detection and mortality in 2020 Geneva, Switzerland year: 2021 ident: e_1_2_8_108_1 – ident: e_1_2_8_57_1 doi: 10.1038/s41564-019-0380-2 – ident: e_1_2_8_59_1 doi: 10.1093/cid/cis732 – ident: e_1_2_8_95_1 doi: 10.1093/infdis/jiz639 – volume-title: BEST (Biomarkers, EndpointS, and other Tools) Resource year: 2016 ident: e_1_2_8_29_1 – ident: e_1_2_8_45_1 doi: 10.1183/13993003.01886-2019 – ident: e_1_2_8_32_1 doi: 10.1172/jci.insight.137427 – ident: e_1_2_8_3_1 doi: 10.3389/fcimb.2022.792617 – ident: e_1_2_8_55_1 doi: 10.1186/1471-2334-13-506 – ident: e_1_2_8_84_1 doi: 10.1016/S1473-3099(20)30914-2 – volume-title: Lateral flow urine lipoarabinomannan assay (LF‐LAM) for the diagnosis of active tuberculosis in people living with HIV: policy update (2019): report user perspectives on TB LAM testing results from qualitative research year: 2019 ident: e_1_2_8_26_1 – ident: e_1_2_8_69_1 doi: 10.1128/jcm.00155-22 – ident: e_1_2_8_23_1 doi: 10.1016/S1473-3099(21)00387-X – ident: e_1_2_8_31_1 doi: 10.1093/cid/ciaa1402 – volume: 45 start-page: 654 year: 2021 ident: e_1_2_8_16_1 article-title: Discovery of serum biomarkers for diagnosis of tuberculosis by NMR metabolomics including cross‐validation with a second cohort publication-title: Biom J – ident: e_1_2_8_88_1 doi: 10.1016/j.ebiom.2021.103787 – volume-title: Consolidated guidelines on tuberculosis: module 2: screening – systematic screening for tuberculosis disease year: 2021 ident: e_1_2_8_105_1 – ident: e_1_2_8_54_1 doi: 10.1093/bib/bby051 – ident: e_1_2_8_70_1 doi: 10.1001/jamanetworkopen.2018.7617 – ident: e_1_2_8_96_1 doi: 10.1161/HYPERTENSIONAHA.120.16340 – ident: e_1_2_8_86_1 doi: 10.1128/JCM.01338-18 – ident: e_1_2_8_64_1 doi: 10.1097/AOG.0000000000003890 – ident: e_1_2_8_12_1 doi: 10.1136/thoraxjnl-2015-207999 – ident: e_1_2_8_87_1 doi: 10.1093/cid/ciz1070 – ident: e_1_2_8_28_1 doi: 10.1186/s12879-020-05243-9 – ident: e_1_2_8_50_1 doi: 10.1097/QAI.0000000000001298 – ident: e_1_2_8_73_1 doi: 10.1038/s41598-019-53086-5 – ident: e_1_2_8_40_1 doi: 10.1016/S1473-3099(20)30928-2 – ident: e_1_2_8_111_1 doi: 10.1016/S0140-6736(15)01316-1 – ident: e_1_2_8_5_1 doi: 10.1056/NEJMoa1303657 – ident: e_1_2_8_15_1 doi: 10.1183/13993003.00655-2019 – ident: e_1_2_8_68_1 doi: 10.1186/s12913-020-4997-x – ident: e_1_2_8_13_1 doi: 10.1038/s41598-018-20855-7 – ident: e_1_2_8_53_1 doi: 10.3389/fpubh.2021.757133 – ident: e_1_2_8_52_1 doi: 10.1371/journal.pone.0218890 – ident: e_1_2_8_66_1 doi: 10.1111/j.1600-0897.2010.00836.x – ident: e_1_2_8_21_1 doi: 10.1128/JCM.00467-17 – ident: e_1_2_8_43_1 doi: 10.1016/j.tibtech.2004.06.005 – volume-title: High‐priority target product profiles for new tuberculosis diagnostics: report of a consensus meeting year: 2014 ident: e_1_2_8_104_1 – ident: e_1_2_8_110_1 doi: 10.3389/fmicb.2019.02789 – ident: e_1_2_8_6_1 doi: 10.1016/j.mib.2017.09.013 – ident: e_1_2_8_34_1 doi: 10.1016/S0140-6736(07)60284-0 – ident: e_1_2_8_47_1 doi: 10.3389/fimmu.2020.00419 – ident: e_1_2_8_89_1 doi: 10.1093/cid/ciab839 – ident: e_1_2_8_67_1 doi: 10.1371/journal.pone.0237574 – ident: e_1_2_8_44_1 doi: 10.18632/oncotarget.11420 – volume-title: Commercial serodiagnostic tests for diagnosis of tuberculosis: policy statement year: 2011 ident: e_1_2_8_102_1 – ident: e_1_2_8_94_1 doi: 10.1093/cid/civ1223 – ident: e_1_2_8_97_1 doi: 10.1016/S1473-3099(18)30111-7 – volume: 36 start-page: 52 year: 2020 ident: e_1_2_8_71_1 article-title: Advances in the diagnosis of pulmonary tuberculosis in children publication-title: Paediatr Respir Rev – ident: e_1_2_8_93_1 – ident: e_1_2_8_39_1 doi: 10.1016/j.tube.2018.09.009 – ident: e_1_2_8_36_1 doi: 10.1038/s41598-017-05057-x – ident: e_1_2_8_61_1 doi: 10.1183/13993003.01718-2020 – ident: e_1_2_8_24_1 doi: 10.1016/S1473-3099(17)30691-6 – ident: e_1_2_8_75_1 doi: 10.1056/NEJMp2118145 – ident: e_1_2_8_74_1 doi: 10.1016/j.jtho.2021.01.1616 – ident: e_1_2_8_11_1 doi: 10.1016/j.tube.2019.04.002 – ident: e_1_2_8_79_1 doi: 10.1371/journal.pone.0016425 – ident: e_1_2_8_7_1 doi: 10.1016/j.ijid.2021.09.010 – ident: e_1_2_8_8_1 doi: 10.1183/13993003.02121-2015 – ident: e_1_2_8_27_1 doi: 10.1016/j.ijid.2020.08.019 – ident: e_1_2_8_42_1 doi: 10.1371/journal.pmed.1002152 – volume-title: Consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection 2021 update year: 2021 ident: e_1_2_8_106_1 – ident: e_1_2_8_58_1 doi: 10.1038/s41598-020-60753-5 – ident: e_1_2_8_14_1 doi: 10.1038/s41598-020-60669-0 – ident: e_1_2_8_91_1 doi: 10.2147/IDR.S345619 – ident: e_1_2_8_37_1 doi: 10.1371/journal.pone.0256883 – ident: e_1_2_8_80_1 doi: 10.3892/mmr.2015.4262 – ident: e_1_2_8_25_1 doi: 10.1038/s41598-020-75513-8 – ident: e_1_2_8_63_1 doi: 10.1038/s43856-022-00086-8 – ident: e_1_2_8_49_1 doi: 10.3389/fimmu.2021.676980 – volume: 7 year: 2020 ident: e_1_2_8_18_1 article-title: Long‐term GeneXpert positivity after treatment for pulmonary tuberculosis publication-title: Eur J Case Rep Intern Med – ident: e_1_2_8_17_1 doi: 10.3389/fimmu.2019.01968 – ident: e_1_2_8_100_1 doi: 10.1038/s41467-018-07635-7 – ident: e_1_2_8_22_1 doi: 10.1183/09031936.00007814 – ident: e_1_2_8_78_1 doi: 10.1016/S1473-3099(14)70884-9 – ident: e_1_2_8_35_1 doi: 10.1093/infdis/jis009 – volume: 8 year: 2018 ident: e_1_2_8_48_1 article-title: Xpert® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance publication-title: Cochrane Database Syst Rev – ident: e_1_2_8_77_1 doi: 10.1371/journal.pone.0098938 – ident: e_1_2_8_81_1 doi: 10.1128/IAI.00649-19 – ident: e_1_2_8_109_1 doi: 10.1016/j.jctube.2021.100284 – ident: e_1_2_8_85_1 doi: 10.1056/NEJMcp2108501 – ident: e_1_2_8_62_1 doi: 10.1016/S2214-109X(21)00045-0 – ident: e_1_2_8_113_1 doi: 10.1371/journal.pone.0126018 – ident: e_1_2_8_20_1 doi: 10.3389/fmicb.2019.01441 – ident: e_1_2_8_98_1 doi: 10.1016/j.tube.2017.08.010 – volume: 163 start-page: 143 year: 2011 ident: e_1_2_8_101_1 article-title: Measurement error in biomarkers: sources, assessment, and impact on studies publication-title: IARC Sci Publ – ident: e_1_2_8_38_1 doi: 10.1093/cid/civ611 – ident: e_1_2_8_99_1 doi: 10.1093/cid/ciaa1083 – volume-title: Xpert MTB/RIF assay for the diagnosis of pulmonary and extrapulmonary TB in adults and children year: 2013 ident: e_1_2_8_103_1 – ident: e_1_2_8_112_1 doi: 10.1164/rccm.201904-0772OC – ident: e_1_2_8_72_1 doi: 10.1016/j.ijmyco.2014.04.003 – ident: e_1_2_8_46_1 doi: 10.1371/journal.pmed.1001538 |
| SSID | ssj0065618 |
| Score | 2.5719988 |
| SecondaryResourceType | review_article |
| Snippet | Tuberculosis (TB) is a leading cause of morbidity and mortality from a single infectious agent, despite being preventable and curable. Early and accurate... Abstract Tuberculosis (TB) is a leading cause of morbidity and mortality from a single infectious agent, despite being preventable and curable. Early and... |
| SourceID | doaj pubmedcentral proquest pubmed crossref wiley springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e14088 |
| SubjectTerms | active TB Biomarkers Child COVID-19 Diagnosis diagnostic biomarkers EMBO02 EMBO23 HIV Human immunodeficiency virus Humans Morbidity Patients Point of care testing Review Tuberculosis Tuberculosis - diagnosis |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB6hChAXBOXRQEFG4gCH0Kzf4cajKw5sxQGk3iLHscVKbRZtdiv13zPjPMoKql44xnEU5_PY_iYefwPwmkdSIJn5fGadyaVtVG5DofLae0NybVE1STL_qzk5saen5bc_Un1RTFgvD9wDdySj543CIdkUtZRO1E6TEyO0bmaiNknnE1nP6Ez1czCSlPRnD9dGbIA2ehD1UVzxo3B-TkfQ0fORRUq4crUeJdn-f3HNv0Mmp33TXVablqX5A7g_8En2of-Oh3ArtPtwp88webkPdxfD3vkjmH_uo-qwIqND9xSXs-4Yklbm0qTHNts6rP32bNUtu_csRW7hPMhc2zA_5lzpHsOP-fH3T1_yIYtC7pUpbR5DVDX2BOclV0Gjv2gcsrSikc5rb3QQMyRRHnlrLZ31zgZuShMFj-hsRGXFE9hrV204AFYoG6J2RhhZSsMbixO91Lq2ZW15FE0G70YsKz9IjFOmi7OKXA0CvyLwqwn8DN5MD_zq1TWur_qROmeqRrLYqQCNpRqMpbrJWDI4HLu2GsZqV5Ffzkm1R2XwarqNo4y2TlwbVluqQ56aQagyeNpbwtQSobHYGp6B2bGRnabu3mmXP5OSd0nJwRS-9-1oTVfNuhYHkcztJryq48ViMV09-x_oPYd7nA5_UDCPOYS9zXobXsBtf7FZduuXaQD-BndYLXQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Biological Science Database dbid: M7P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BeYgLjwIlUFCQOMAhNGvHj3BBPLriwFY9gNRb5PgBK7VJm-wi8e_xOE5WKygcOMZxFNsznodn_A3AC-IQgWSms5lUIiukYZm0OctqrQXCtTlmAmT-Z3F0JE9OyuN44NbHtMpRJgZBbVqNZ-QH6D0RxFZhb88vMqwahdHVWELjKlxDlAQaUveOR0nsTZVwvuc1pB8GFzxC-zDCyIE9O8OL6N7_KfJQdmWjlQJ4_58szt8TJ6fo6bZtG5TT_M7_Tusu3I5mafpu4KN7cMU2u3BjKFT5cxduLmII_j7MPw7Jeb5jinf3Mb2n61Nv-6YqyM50ta5tp9enbb_s36QhAcyL01Q1JtVj6Zb-AXydH3758CmLxRgyzUQpM2cdqz1BCSkJs9y7nUJ5Yy83hdJcC27pzNti2pu_daGkVtISUQpHifM-i2OSPoSdpm3sI0hzJq3jSlBRlH72Rnp9UXBey7KWxFGTwOuRGJWOSOVYMOO0Qo8FqVch9aqJegm8nD44H0A6Lu_6Hqk7dUN07dDQdt-quFmrwmlimFcDJq-LQtFacXScKedmRmtBE9gfiVnFLd9XG0om8Hx67TcrRmBUY9s19kGHT_ilSmBvYKVpJJT7ZilIAmKLybaGuv2mWX4PgOAl1hhj_r-vRnbcDOvSdaCBX_-1XtXhYrGYnh7_feJP4BbB2yGY7SP2YWfVre1TuK5_rJZ99yzszV_4uTxb priority: 102 providerName: ProQuest |
| Title | Diagnostic biomarkers for active tuberculosis: progress and challenges |
| URI | https://link.springer.com/article/10.15252/emmm.202114088 https://onlinelibrary.wiley.com/doi/abs/10.15252%2Femmm.202114088 https://www.ncbi.nlm.nih.gov/pubmed/36314872 https://www.proquest.com/docview/2747230825 https://www.proquest.com/docview/2730647314 https://pubmed.ncbi.nlm.nih.gov/PMC9728055 https://doaj.org/article/4fc2d5911d0b44a3ba60614366d13b73 |
| Volume | 14 |
| WOSCitedRecordID | wos000876419000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1757-4684 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0065618 issn: 1757-4676 databaseCode: DOA dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1757-4684 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0065618 issn: 1757-4676 databaseCode: M7P dateStart: 20090401 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1757-4684 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0065618 issn: 1757-4676 databaseCode: 7X7 dateStart: 20090401 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1757-4684 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0065618 issn: 1757-4676 databaseCode: BENPR dateStart: 20090401 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database (ProQuest) customDbUrl: eissn: 1757-4684 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0065618 issn: 1757-4676 databaseCode: PIMPY dateStart: 20090401 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1757-4684 dateEnd: 20231231 omitProxy: false ssIdentifier: ssj0065618 issn: 1757-4676 databaseCode: WIN dateStart: 20090101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Open Access customDbUrl: eissn: 1757-4684 dateEnd: 20231231 omitProxy: false ssIdentifier: ssj0065618 issn: 1757-4676 databaseCode: 24P dateStart: 20090101 isFulltext: true titleUrlDefault: https://authorservices.wiley.com/open-science/open-access/browse-journals.html providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEA96q-KLH-dX9Vwq-KAPPbf5rm-e7uKBuxRRXJ9Kmqa6cNeVdlfwv3cm_ZCihyC-BNqkbTqZycwkk98Q8pSWiEAS2yjWRkVcFyLSbiai3FqFcG2lKDxk_ju1Wun1Okm7aEI8C9PiQwwLbigZfr5GATd502fsQdRQd36OR8nBg-EgKpfJJI6ZxuwNlKf9ZAzWil_iAyUJPZFKdug--IoX4xeMFJPH7_-T0fl77OSwgTo2b71-Wtz8D392i9zojNPwVctNt8klVx2Sq226yh-H5Nqy24i_QxZv2hA9aBjiCX4M8qmbECzg0PgZNNztc1fb_dm22TQvQx8GBpNqaKoitH0Cl-Yu-biYf3j9NupSMkRWqERHpStFDsNKaUKFk-B8KgMm36zgxkqrpGMxWGQWjOCcG22NdlQlqmS0BM-lFJrdIwfVtnIPSDgT2pXSKKZ4whUtNGgNLmWuk1zTkhUBOe7HI7MdXjmmzTjL0G9BSmVIp2ygU0CeDQ98a6E6Lm56ggM8NEOMbX9jW3_JOpHNeGlpIUAZFLOcc8NyI9F9ZlIWMcsVC8hRzx5ZJ_hNhk4-RQggEZAnQzWILO7DmMpt99gG3T4FpArI_Zabhp4wCbe1ogFRIz4bdXVcU22-eljwBDONCfju854jf3XrQjowz4h_o1c2Xy6Xw9XDf3rqEblO8egIhgKpI3Kwq_fuMbliv-82TT31UgulWitf6imZnMxX6fupXyWZYkwu1E_S02X6Ga4-na5-AsQ-RxY |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwEB6V8rzwKK9AgSCBBIfQXTt-BAkhoF216m7VQyv1FhzHgZXabNnsgvqn-I3MOI_VCgqnHjgm8W7syXjmG3v8DcALVhADSd9GfW1UFOtcRNr1RJRZq4iurRC5p8wfqr09fXSU7K_Az_YsDKVVtjbRG-p8YmmNfIOiJ0bcKuL96beIqkbR7mpbQqNWi1139gNDturdziZ-35eMDbYOPm1HTVWByAqV6KhwhciwZ4wlTDiJ8ZMyiFp6eWystEo63kdQYRHHZbHR1mjHVKIKzgoE34XQHP_3ElxGGMG0TxXcby0_QiO_nogeGYctlWyohAQTbMOdnNDBd4y34p4v87Lwgr5YwJ8Q7u-Jmt1u7TKW9s5wcOt_E-NtuNnA7vBDPU_uwIor1-BqXYjzbA2ujZoUg7sw2KyTD7FhSNwElL40rULE9qHxviGczTM3tfPjSTWu3oY-wQ3dRWjKPLRtaZrqHhxeyHjuw2o5Kd1DCHtCu0IaxVWcoLRzjf4wljLTSaZZwfMA3rQfP7UNEzsVBDlOKSIjbUlJW9JOWwJ41f3gtCYhOb_pR9Kmrhmxh_sbk-mXtDFGaVxYlgt0c3kvi2PDMyNpYYBLmfd5pngA663ypI1Jq9KF5gTwvHuMxoh2mEzpJnNqQwGtQlEF8KBW3a4nXOJtrVgAakmpl7q6_KQcf_WE5wnVUBP43tet-i-6da4cuJ8f_5JXujUajbqrR38f-DO4vn0wGqbDnb3dx3CD0UkYymxS67A6m87dE7hiv8_G1fSptwshfL7oGfQL3dOXaQ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB6VAhUXHuVlKGAkkOjBxFl7H0ZCCEgjqjZRDiD1ZtbrNURqnRInoP41fh0z60cUQeHUA8fYm2Q9_ua1O_sNwDNWEANJ3wR9pWUQq5wHyoY8yIyRRNdW8NxR5h_K8VgdHSWTDfjZnoWhssrWJjpDnc8MrZH3KHtixK3Ce0VTFjEZDN-cfguogxTttLbtNGqIHNizH5i-Va_3B_iunzM23Pv4_kPQdBgIDJeJCgpb8AxnyVjCuBWYS0mNEUyYx9oII4WN-hhgGIzpslgro5VlMpFFxAoMxAuuIvzdS3BZEmm5KxuctF4AwyS3tojeGUUgpGhohTjjrGdPTugQPOZecehavqw8omsc8Kdo9_eizW7ndj2udo5xeON_FulNuN6E4_7bWn9uwYYtt-Fq3aDzbBu2Rk3pwW0YDuqiRBzoE2cBlTXNKx9jfl87n-Evlpmdm-XxrJpWr3xX-IZuxNdl7pu2ZU11Bz5dyPPchc1yVtr74Idc2UJoGck4QcnnCv1kLESmkkyxIso9eNkCITUNQzs1CjlOKVMj5KSEnLRDjgcvui-c1uQk5w99R8jqhhGruLswm39JGyOVxoVhOUf3l4dZHOso04IWDCIh8n6UyciDnRZIaWPqqnSFIg-edrfRSNHOky7tbEljKNGVKCoP7tUw7mYSCbysJPNArgF8barrd8rpV0eEnlBvNY7_u9uqwmpa58ohcrryL3mle6PRqPv04O8P_gS2UHHSw_3xwUO4xuiADBU8yR3YXMyX9hFcMd8X02r-2JkIHz5ftAL9AoafoCY |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Diagnostic+biomarkers+for+active+tuberculosis%3A+progress+and+challenges&rft.jtitle=EMBO+molecular+medicine&rft.au=Nogueira%2C+Bet%C3%A2nia+M+F&rft.au=Krishnan%2C+Sonya&rft.au=Barreto%E2%80%90Duarte%2C+Beatriz&rft.au=Ara%C3%BAjo%E2%80%90Pereira%2C+Mariana&rft.date=2022-12-07&rft.issn=1757-4676&rft.eissn=1757-4684&rft.volume=14&rft.issue=12&rft_id=info:doi/10.15252%2Femmm.202114088&rft.externalDBID=n%2Fa&rft.externalDocID=10_15252_emmm_202114088 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1757-4676&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1757-4676&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1757-4676&client=summon |